Pedunculopontine tegmental (PPT) GABAergic system plays a crucial role in the regulation of rapid eye movement (REM) sleep. We recently reported that the activation of PPT GABA-B receptors suppressed REM sleep by inhibiting REM-on cells. One of the important mechanisms for GABA-B receptoractivation-mediated physiological action is the inhibition of intracellular cAMP-dependent PKA (cAMP-PKA) signaling pathway. Accordingly, we hypothesized that the PPT GABA-B receptor activationmediated REM sleep suppression effect could be mediated via inhibition of cAMP-PKA activation. To test this hypothesis, a GABA-B receptor selective agonist, Baclofen hydrochloride (Baclofen), cAMP-PKA activator, Sp-Adenosine 3',5'-cyclic monophosphothioate triethylamine (SpCAMPS), and vehicle control were microinjected into the PPT in selected combinations to determine effects on sleep-waking states of chronically instrumented, freely moving rats. Microinjection of SpCAMPS (1.5 nmol) induced REM sleep within a short latency (12.1 ± 3.6 minutes) compared to vehicle control microinjection (60.0 ± 6.5 minutes). On the contrary, microinjection of Baclofen (1.5 nmol) suppressed REM sleep by delaying its appearance for about 183 minutes; however, the suppression of REM sleep by Baclofen was prevented by a subsequent microinjection of SpCAMPS. These results provide evidence that the activation of cAMP-PKA within the PPT can successfully block GABA-B receptor activation mediated REM sleep suppression effect. These findings suggest that the PPT GABA-B receptor activationmediated REM sleep regulating mechanism involves inactivation of cAMP-PKA signaling in the freely moving rat.
INTRODUCTION
Research in the past ten years, ranging from developmental maturation to genetic model of Alzheimer's, have provided evidence that the cholinergic cells in the pedunculopontine tegmentum (PPT) and laterodorsal tegmentum (LDT) are critically involved in the physiological regulation of rapid eye movement (REM) sleep (Datta 1995; Deuerveilher and Hennevin 2001; Garcia-Rill 1997; Kobayashi et al. 2004a,b; Zhang et al. 2005) . The PPT, situated in the dorsolateral mesopontine tegmentum, contains a prominent group of cholinergic and some non-cholinergic neurons, which project widely throughout the brainstem and forebrain (for reviews, see Datta 1995; Garcia-Rill 1991; Jia et al. 2003; Jones 2004; Lai et al. 1993) . Single cell recordings from the PPT/LDT of behaving cats and rats have identified several different types of cells whose firing rates correlate with both wakefulness and REM sleep (Datta 1995; Datta and Siwek 2002; El-Mansari et al. 1989; Steriade et al. 1990; Thakkar et al. 1998) . Some of the recent pharmacological studies in cats and rats have demonstrated that the activation of PPT kainate type glutamate receptors induces REM sleep (Datta 2002; Datta et al. 2002; Datta and Siwek 2002) . Other studies have demonstrated that the activation of PPT GABA-B receptors inhibit PPT REM-on cells activity and suppresses REM sleep (Datta et al. 2003; Ulloor et al. 2004) . Despite tremendous progress in the identification of specific neurotransmitters and receptors involved in the regulation of the PPT cells neuronal activity and REM sleep, very few attempts have been made to study the possible intracellular signal transduction mechanisms of the PPT that may be involved in the regulation of REM sleep.
It is known that the GABA-B receptors couple to Gi/Go G-proteins (Couve et al. 2000; Kerr and Ong 1995; Mody et al. 1994; Robbins et al. 2001; Sivilotti and Nistri 1991; Takahashi et al. 1998; Thompson 1994) . It is also known that Gi/Go G-proteins inhibit adenylyl cyclase (AC) and inhibition of AC prevents activation of the cAMP-PKA signal transduction pathway (Gilman 1987; Marinissen and Gutkind 2001) . Since it has been demonstrated that the activation of GABA-B receptors within the PPT suppresses activity of REM-on cells and REM sleep in the freely moving rat (Ulloor et al. 2004) , it is reasonable to suggest that the PPT GABA-B receptor activation-induced suppression of REM sleep may have been caused by the inhibition of AC that ultimately prevented activation of cAMP-PKA. In support of this suggestion, two recent studies have demonstrated that the local application of drugs that inhibit Page 3 of 37 4 AC activity and cAMP-PKA activation in the PPT suppress REM sleep (Bandyopadhya et al. 2006; Datta and Prutzman 2005) . Although, these two studies have demonstrated that the inhibitions of both AC and cAMP-PKA activation in the in the PPT suppresses REM sleep (Bandyopadhya et al. 2006; Datta and Prutzman 2005) , no studies have shown that the activation of either AC or cAMP-PKA in the PPT could increase REM sleep. It has also not been shown that the GABA-B receptor activation-mediated REM sleep suppression effect could be rescued and/or bypassed by the activation of intracellular cAMP-PKA.
In the present study, we examined the changes in sleep-wake behavior of freely moving rats after activation of cAMP-PKA, GABA-B receptor, or both cAMP-PKA and GABA-B receptor within the PPT. Our results show that the activation of PPT cAMP-PKA induces REM sleep. While activation of PPT GABA-B receptors suppresses REM sleep, these results also show that the activation of cAMP-PKA could rescue REM sleep from the GABA-B receptor activation-induced suppression. The results of these experiments indicate that, in the PPT, GABA-B receptor activation mediated REM sleep regulation involves inactivation of cAMP-PKA system.
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METHODS
Subjects and housing
Experiments were performed on 28 adult male Sprague-Dawley rats (Charles River, Wilmington, MA) weighing between 250 and 350 g. The rats were housed individually at 24°C with food and water provided ad libitum with lights on from 7 AM to 7 PM (light cycle) and off from 7 PM to 7 AM (dark cycle). The principles for the care and use of laboratory animals in research, as outlined by the National Institutes of Health Publication No. 85-23 (1985) were strictly followed.
Drug and vehicle for microinjections
In this study, GABA-B receptors in the PPT were activated by a GABA-B receptor-specific agonist, Baclofen hydrochloride (Baclofen; molecular weight: 250.13), purchased from Sigma chemicals (St. Louis, MO, USA). The selection of Baclofen was based on the selective agonistic effects on GABA-B receptors (Bowery 1993; Enna and Maggi 1979; Falch et al. 1986; Fromm et al. 1990; Hill and Bowery 1981; Hong and Henry 1991; Kerr and Ong 1995; Misgeld et al. 1995; Paredes and Agmo 1989; Ulloor et al. 2004 ). In addition to specificity, above studies have shown that Baclofen is readily soluble in water and accessible to extracellular receptors. The Baclofen was dissolved in 0.9% saline to make 1.5 nmol/100 nl dose. The optimum dose of Baclofen (1.5 nmol/100 nl) was predetermined from our earlier dose-response study (Ulloor et al. 2004) . Another drug used in this study was an activator of cAMP-PKA activity, Sp-cAMPS triethylamine (SpCAMPS; Mol. Wt. 446.46), also purchased from Sigma chemicals (St. Louis, MO, USA). The selection of this drug was based on the selective activation effect on intracellular cAMP-PKA activity (Cook et al. 1995; Capece and Lydic 1997; Punch et al. 1997; Wang et al. 1991) . In addition to the selectivity, SpCAMPS was suitable for this study because these studies have shown that it is water-soluble, cell membrane permeable, has reversible effects, and it has been used successfully in microinjection studies in behaving animals (Cook et al. 1995; Capece and Lydic 1997; Punch et al. 1997; Wang et al. 1991 Wang et al. , 1993 . The SpCAMPS was dissolved in 0.9% saline to make 1.5
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Surgical Procedures and Implantation of Electrodes
Treatment of the animals and surgical procedures were in accordance with an approved institutional animal welfare protocol (AN-14084). Efforts were made to minimize the number of animals used and their suffering. Rats were anesthetized with pentobarbital (40 mg/kg, i.p.), placed in the stereotaxic apparatus, and secured using blunt rodent ear bars (Paxinos and Watson, 1997) . With the use of sterile procedures, cortical electroencephalogram (EEG), dorsal neck muscle electromyogram (EMG), and hippocampal EEG (to record theta waves) recording electrodes were chronically implanted, as described elsewhere (Datta 2000) . In addition, stainless steel guide tube (26 gauge), with an equal-length stylett inside, stereotaxically implanted 2 mm above the PPT (in relation to sterotaxic "0": anterior, 1.0 mm; lateral, 1.8 mm; and horizontal, 3.0 mm) as described previously (Datta 2002; Datta et al. 2002) .
Intracerebral microinjections and experimental design
After the adaptation recording sessions, microinjection sessions began. During experimental sessions, animals were connected to the polygraphic recording system 15-minutes before the first microinjection into the PPT. The microinjection system consisted of a 32-gauge stainless steel injector cannula with a 26-gauge collar that extended 2.0 mm beyond the implanted guide tube. The collar was connected to a 1.0 µl motor-driven Hamilton microsyringe with PE 20 tubing. In this study, a doublemicroinjection protocol was adopted as described earlier (Datta 2002; Datta et al. 1993) . Briefly, each microinjection session consisted of two injections in the same site with a 15-min interval between the first and second injections. While the animal was connected to the recording system, the stylett was removed and a control vehicle-filled (100 nl volume of 0.9% saline) or any one of the two drugs-filled (1.5 nmol in 100 nl, SpCAMPS or Baclofen) injector was introduced through the guide tube for the first injection. One minute after the insertion of the injector cannulae, 100 nl of control saline or any one of the two drugs was microinjected over a 60-s period (Pump II Pico Plus, Harvard Apparatus, Holliston, Page 6 of 37 7 MA). The cannula was gently withdrawn 2 minutes after the injection, and the stylett was reintroduced inside the guide tube. For the second injection, control saline or SpCAMPS was injected into the same site using the same injector system as described for the first injection. During the microinjections, animals were free to move around the cage with the cannulae in place. Due to the extended tubing, the injections could be made without restraining mobility of the animal. Immediately after completion of the microinjection procedure, polygraphic variables were recorded continuously for six-hours (between 10 AM and 4 PM), when rats would normally be sleeping (Datta, 2000) . Each of these rats received a total of 2 microinjections (100 nl each) into the PPT (left or right side) in a single experimental recording session. None of the rats were used for more than one microinjection recording session.
The injection protocol was designed so that 28 rats were divided equally into four groups (n = 7 rats/group). The first group received saline + saline injections (control group) into the PPT. The second group received Baclofen + saline injections (GABA-B receptor activation group) into the PPT. The third group received Baclofen + SpCAMPS injections (GABA-B receptor + PKA activation group) into the PPT. The fourth group received SpCAMPS + saline injections (PKA activation group) into the PPT. At the end of experimental session and before perfusion, with the use of same injector used for saline or drugs, 100 nl of black ink was microinjected 1 mm dorsal to each injection site for localizing the injection sites as described earlier (Datta 2002; Datta et al. 2001) .
Determination of behavioral states and data analysis
For the purpose of determining possible effects on sleep and wakefulness, polygraphic data were captured on-line in a computer using "Gamma" software (Grass product group, Astro-Med, West Warwick, RI). From this captured data, three behavioral states were distinguished and scored visually using "Rodent Sleep Stager" software (Grass product group, Astro-Med) as described earlier ( The effects of the four different treatments (1. saline + saline; 2. Baclofen + saline; 3. Baclofen + SpCAMPS; 4. SpCAMPS + saline) on the percentages of W, SWS, and REM sleep were statistically analyzed using a two-way ANOVA with time as a repeated measure variable (six levels corresponding to six one-hour epochs following injections) and treatment as a between-group variable (four levels corresponding to the four different treatment groups). Following a two-way ANOVA, post-hoc Scheffe-F tests were done to determine the individual levels of significant difference between the control (saline + saline) and the three different drug treatment protocols at six individual data points. Individual post-hoc tests were also done to compare between three different drug treatment protocols. The latency, number, and duration of REM sleep episodes were analyzed using a one-factor ANOVA followed by post-hoc Scheffe-F tests. Statistical analyses (two-way ANOVA, one-factor ANOVA, and Scheffe F-test) were performed with the use of StatView statistical software (Abacus Concepts, Berkeley, CA).
Histological localization of injection site
At the conclusion of the microinjection experiments, rats were deeply reanesthetized with pentobarbital (60 mg/kg, i.p.) and perfused transcardially with heparinized cold phosphate buffer (0.1 M, pH 7.4) followed by 4% paraformaldehyde in 0.1 M phosphate buffer. The brains were removed and processed for NADPH-diaphorase staining and histological localization of injection sites as described earlier (Datta 2002; Datta et al. 2001 ). This NADPH-diaphorase staining was done to identify the cholinergic cell compartment of the PPT (Bredt et al. 1991; Bredt and Snyder 1992; Datta 2002; Datta et al. 1997; Hope et al. 1991; Vincent et al. 1983) .
RESULTS
(Insert Figure 1)
Page 8 of 37 Figure 1 illustrates the anatomical location of microinjection sites. Histological identification showed that all four combinations of microinjections (control saline + saline, Baclofen + saline, Baclofen + SpCAMPS, and SpCAMPS + saline) were within the PPT (Fig. 1) . The microinjection sites were anatomically comparable between four different treatment groups, therefore, the analysis below quantifies the effects of Baclofen + saline (n=7 rats), Baclofen + SpCAMPS (n=7 rats), and SpCAMPS + saline (n=7 rats) microinjected into the PPT on the W, SWS, and REM sleep states. However, after Baclofen + SpCAMPS microinjections, REM sleep latency was shorter than after saline + saline and after Baclofen + saline microinjections. Microinjections of Baclofen + saline decreased latency of the first episode and increased duration of each SWS episodes compared with after saline + saline, SpCAMPS + saline, or Baclofen + SpCAMPS. For about 2 hours after microinjections of SpCAMPS + saline, Baclofen + saline, and Baclofen + SpCAMPS, the duration of W episodes were shorter compared with after saline microinjections. These results demonstrate that these microinjections into the PPT did, in fact, change the sleep-wake architecture of the rat.
(Insert Figure 3)
Effects on Wakefulness
The changes in the percentage of time spent in W after microinjections are summarized in Fig. 3 . Two-way ANOVA indicated a significant main effect of treatment (df = 3, F = 9.32, p<0. 1997; Datta et al. 2001a Datta et al. , b, 2002 Garcia-Rill 1991; Garcia-Rill et al. 1990 , 2001 Radulovacki et al. 2004 ). Thus, the activation or inhibition of PPT cells correspondingly increases or decreases REM sleep. In addition to the suppression of REM sleep, our results demonstrated that the activation of GABA-B receptors in the PPT reduces the total percentages of wakefulness. This observation is also Page 13 of 37 14 consistent with the observation of another study that has shown intra-cerebro-ventricular application of GABA-B receptor antagonist increases wakefulness and REM sleep in the rat (Gauthier et al. 1997) .
Consistent with the suggestion that the GABAergic system could modulate the physiological activity of PPT cells as well as behavioral states of wakefulness and REM sleep is also supported by anatomical studies that have shown the PPT receives GABAergic inputs from the substantia nigra, local neurons, and many other parts of the brain (Beckstead 1982; Carpenter et al. 1981; Jackson and Crossman 1981; Jia et al. 2003; MoonEdley and Graybiel 1983; Reese et al. 1995; Scarnati and Florio 1997; Scarnati et al. 1988; Steininger et al. 1992) . The possibility that endogenous GABAergic neurotransmission in the PPT may modulate PPT cell activity is also supported by the presence of different types of GABA receptors and GABAergic fibers in the PPT (Bowery et al. 1987; Chu et al. 1990; Kosaka et al. 1987; Mugnaini and Oertel 1985) . Collectively, the results of the current study and results of earlier studies discussed above, provide conclusive evidence to support that the endogenous GABA released in the PPT regulates physiological REM sleep and wakefulness by activating GABA-B receptors.
The present study demonstrates that the activation of PPT cAMP-PKA by local application of SpCAMPS, an activator of cAMP-PKA activation, increases REM sleep. This result suggests that the activation of PPT cAMP-PKA is involved in the generation of REM sleep. Since earlier studies have shown that the inhibition of AC (Datta and Prutzman 2005) and cAMP-PKA (Bandyopadhya et al. 2006) in the PPT suppresses REM sleep, it is reasonable to suggest that the cAMP-PKA intracellular signaling system in the PPT is critically involved in the regulation of PPT cell activity and REM sleep. Besides these studies, a number of other studies in behaving cats and rats have looked at the involvement of signal transduction pathways in the pontine reticular formation (PRF), another site known to be involved in the regulation of REM sleep (Capece and Lydic 1997; Marks and Birabil 2000; Shuman et al. 1995) .
These studies have indicated that the signal transduction pathway activated by muscarinic cholinergic receptors involves a pertussis toxin-sensitive G protein, AC, cAMP, and PKA. In the rat, this signal transduction pathway in the PRF is also shown to be involved in spontaneous REM sleep (Marks and Birabil 2000) . Thus, it is reasonable to conclude that depending on the anatomical site and involved (Garcia-Rill 1997; Garcia-Rill et al. 2003; Rye 1997) , there may be a convergence of mechanisms at the level of the brain stem. Therefore, the results of these experiments will be important in developing rational schematics of pharmacological therapies for these persistent and debilitating disorders.
We chose to study chronically implanted freely moving rats because this preparation provides the most physiological approach to a longitudinal analysis of the behavioral and electrographic events related to the wake-sleep cycle (Datta et al. 2002; Datta and Siwek 2002; Ulloor et al. 2004) . After the accommodation period of each experimental condition, the rats demonstrated regular values of wake and sleep stages. Thus, the microinjections of a pharmacologically active selective signal transductionPage 15 of 37 16 altering activator that affected electrographic signs of wake-sleep patterns could be evaluated accurately (Capece and Lydic, 1997; Marks and Birabil, 2000) . Moreover, understanding the role of the intracellular signal transduction pathway in a behaviorally active living organism is a vital step towards creating ways to converge functional biochemistry and integrative physiology. However, a major limitation of the microinjection method relates to the diversity in the neurochemical and functional nature of the neuronal population affected by the drug application. In this study, a GABA-B receptor selective antagonist, baclofen, and a selective activator of cAMP-PKA, SpCAMPS, were microinjected into the PPT. We injected these drugs into the part of the PPT (pars compacta) where most cells are known to be cholinergic (Mesulum et al. 1983; Rye et al. 1987 ) and express REM-on type of activity (Datta and Siwek, 2002) . Nonetheless, we acknowledge that if there are non-cholinergic and REM-off cells are located within the targeted site, they will also be affected by the application of these drugs. Another limitation of microinjection method is the extent of diffusion of injected materials. In recent years, several laboratories, including our own, have improved this technique tremendously in many different ways. Recent microinjection studies have shown that a major advantage of the microinjection technique is its ability to stimulate a relatively circumscribed neuronal pool (Bandyopadhya et al. 2006; Capece and Lydic 1997; Datta et al. 2001a Datta et al. ,b, 2003 Marks and Birabil 2000) . This view is supported by biophysical studies of drug diffusion (Nicholson 1985) , and distribution kinetics (Herz and Teschemacher 1971; Martin 1991) . Diffusion data obtained from radiolabeled drug studies show that 30 min after brain microinjections of 500 nl volumes, 72% of the drug remained within a radius of 0.75 mm (Yaksh and Rudy 1978) . In this study, the target area of the 100 nl drug solutions injected into the PPT (approximate size: length: 1.0; height: 1.0; and width: 0.8 mm), were well within the diffusion limit of this small volume. Moreover, in our recent microinjection mapping study in the PPT, it has been demonstrated that 100 nl of glutamate with drug concentrations similar to those used in this proposal, were ineffective when injections were 0.5 mm away from the center of the PPT site (Datta 2002; Datta et al. 2001a,b; ) .
Additionally, using similar microinjection technique, we have demonstrated that ibotenic microinjectioninduced cell loss in the brainstem of rats was limited to a maximum radius of 0.35 mm. Other sleep-wake related structures that are close to the PPT microinjection sites are the LDT and subcoeruleus nucleus.
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These two structures are approximately one mm away from the PPT microinjection sites. Thus, it is highly improbable that microinjected drugs used in this study (100 nl volume and 1.5 nmol dose) diffused into the LDT and subcoeruleus nucleus.
The results of the present study also confirm a well-established fact that the activation of PPT is positively involved in the regulation of REM sleep (for reviews see Datta 1995; McCarley 2004) .
Contrasting this view, a recent publication claimed that the total amount of REM sleep increases in the rat after PPT lesion (Lu et al. 2006) . This study also claimed that lesioning the subcoeruleus alpha (Datta and Siwek 1997; Datta et al. 2001a; Garcia-Rill 1991; Garcia-Rill et al. 1987 ). On the other hand, using an excitotoxin lesion technique, studies have shown that the elimination of PPT cells suppresses motivational behaviors (Bechara and van der Kooy 1989, 1992; Olmstead and Franklin 1993) ; and consequently PPT lesioned rats spend more time in quiet wakefulness by reducing active wakefulness. Cortical EEG waves amplitudes and frequencies are very similar during quiet wakefulness and REM sleep (Datta and Hobson 2000) . During quiet wakefulness, EMG sign of muscle tone in the rat is also very low, especially in PPT lesioned rats. Thus, it is possible that while identifying sleep-wake states, Lu and his colleagues (Lu et al. 2006 ) might have misidentified some quiet wake episodes as REM Page 17 of 37 18 sleep episodes. It is also known that the lesion of nucleus subcoeruleus alpha suppresses REM sleep muscle atonia (Hendricks et al. 1982; Sakai 1980; Sanford et al. 2001; Shouse and Siegel 1992) . Despite a reduction in REM sleep muscle atonia in these lesioned animals, the total amount of REM sleep is relatively unchanged. Similar to REM sleep muscle atonia, it has also been demonstrated that the lesion of P-wave (one of the cardinal features of REM sleep) generator, suppresses P-wave activity in the rat and cat during REM sleep (Datta and Hobson 1995; Mavanji et al. 2004 ). In these P-wave generator lesioned rats and cats, the total amount of wakefulness, SWS, and REM sleep remains relatively unchanged. Therefore, in these REM sleep sign generator lesioned animals, identification of REM sleep is relatively more challenging than the identification of sleep-wake states in the normal animals. It is likely that the SLD lesioned rats of Lu et al. (2006) do not change total amount of REM sleep or wakefulness (Mavanji et al. 2004; Sanford et al. 1994 ).
In conclusion, the present study shows that the inactivation of cAMP-PKA in the PPT is a critical step for the GABA-B receptor-activation-mediated regulation of REM sleep. The results also suggest that the activation of cAMP-PKA in the PPT is an important step to induce REM sleep. These data provide a novel perspective on the regulatory aspect of PPT cells' activity in the regulation of REM sleep. These novel findings are critical for our complete understanding of the basic mechanisms in REM sleep regulation. 
